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In Brief
Monypenny et al. show that the ESCRT-
related protein ALIX regulates two
clinically important proteins in breast
cancer; namely, EGFR, a receptor linked
to cell survival, and PD-L1, an immune
checkpoint protein. ALIX is, therefore,
associated with pathways that drive both
cell-autonomous and non-cell-
autonomous mechanisms of tumor
survival.
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The immunosuppressive transmembrane protein
PD-L1 was shown to traffic via the multivesicular
body (MVB) and to be released on exosomes. A
high-content siRNA screen identified the endosomal
sorting complexes required for transport (ESCRT)-
associated protein ALIX as a regulator of both
EGFR activity and PD-L1 surface presentation in
basal-like breast cancer (BLBC) cells. ALIX depletion
results in prolonged and enhanced stimulation-
induced EGFR activity as well as defective PD-L1
trafficking through the MVB, reduced exosomal
secretion, and its redistribution to the cell surface.
Increased surface PD-L1 expression confers an
EGFR-dependent immunosuppressive phenotype
on ALIX-depleted cells. An inverse association
between ALIX and PD-L1 expression was observed
in human breast cancer tissues, while an immuno-
competent mouse model of breast cancer revealed
that ALIX-deficient tumors are larger and show an
increased immunosuppressive environment. Our
data suggest that ALIX modulates immunosuppres-630 Cell Reports 24, 630–641, July 17, 2018 ª 2018 The Author(s).
This is an open access article under the CC BY license (http://creativesion through regulation of PD-L1 and EGFR and
may, therefore, present a diagnostic and therapeutic
target for BLBC.INTRODUCTION
Epidermal growth factor receptor (EGFR) is either amplified or
mutated in a variety of cancers and contributes significantly to
tumorigenesis (Chong and Ja¨nne, 2013; Ciardiello and Tortora,
2008). Basal-like breast cancer (BLBC), a subtype of disease
with the worst therapeutic outcomes, commonly exhibits
elevated EGFR expression (Burness et al., 2010; Irshad et al.,
2011). While the subject of intense research, the complexity
and plasticity of the tumor EGFR signaling network may underlie
the poor response to current EGFR-targeted therapies (Hudis
and Gianni, 2011). Thus, there is a need to seek additional
molecular targets for improving EGFR targeting in basal-like
disease.
Immune checkpoint blockade has introduced exciting
possibilities to the field of targeted cancer therapy to inhibit
tumor growth, with exploitation of programmed death-ligand 1
(PD-L1) showing great therapeutic promise (Pardoll, 2012).
The recent demonstration of a direct association between
activating EGFR mutations and increased PD-L1 expression incommons.org/licenses/by/4.0/).
Figure 1. Biochemical Validation of the
Picchu-X EGFR Activity Biosensor
(A) Lysates of cells transiently expressing the
Picchu-X biosensor were examined by western
blotting with the indicated antibodies.
(B) Donor fluorescence lifetime and intensity im-
ages for representative Picchu-X-expressing cells
subjected to the indicated treatments. A PD16838-
sensitive decrease in donor fluorescence lifetime is
observed following treatment with EGF.
(C) Quantification of average FRET efficiencies for
treatment groups shown in (B). Data are mean
FRET efficiencies, and error bars represent SEM. n
R 12 for each group; significance determined us-
ing Student’s t test (*p < 0.05). n.s., not significant.
(D) Population distribution of mean cell fluores-
cence lifetimes versus mean fluorescence in-
tensities for Picchu-X-expressing cells treated as
indicated. Donor fluorescence intensities (top) and
associated lifetime maps (bottom) are indicated
for two example cells with high (solid arrow) and
low (empty arrow) levels of Picchu-X biosensor
expression. Scale bar, 40 mm.
(E) Three-way correlation analysis of biosensor
donor lifetime, biosensor expression, and ligand
treatment. Data related to lifetime, biosensor
expression, and ligand treatment for all cells
included in the siRNA library screen were included
in the correlation analysis. Two-tailed Pearson
correlation coefficient (r) reported a statistically
significant association between intensity and t (p < 0.01). The difference in t between treatment groups (t = t-statistic value) was highly significant (p < 0.001) and
incorporates the significant association between intensity and t. There was no significant association between intensity and treatment (p = 0.24).non-small-cell lung cancer has shown an interdependence be-
tween cancer cell-autonomous (EGFR-dependent cell survival)
and non-autonomous (PD-L1-dependent evasion of immune
surveillance) mechanisms of tumor survival (Akbay et al., 2013;
Murillo et al., 2014). Consequently, tumors harboring activating
EGFR mutations benefit from two distinct but linked survival
pathways, and targeting of mutant EGFR can impair the immu-
nosuppressive phenotype of these tumors (Chen et al., 2015).
However, targeting of wild-type receptors in human lung cancer
cell lines has little effect on PD-L1 expression (Azuma et al.,
2014), suggesting that the link between EGFR and PD-L1
expression is dependent on the kinase activity of the receptor
(Akbay et al., 2013; Azuma et al., 2014). In BLBC, PD-L1 expres-
sion is frequently observed alongside elevated wild-type EGFR
expression (Irshad et al., 2011; Nielsen et al., 2004), suggesting
that the immunosuppressive characteristics of these tumors
may be refractory to the effects of therapies targeting EGFR’s
kinase activity. A greater understanding of mechanisms driving
EGFR signaling in breast cancer is, therefore, warranted; in
particular, how EGFR activity in this disease affects immunosup-
pressive pathways mediated by PD-L1.
Here, we performed a bioinformatics-led RNAi screen in BLBC
cells to identify regulators of EGFR activity. Among proteins
identified were exosomal cargo proteins and proteins implicated
in exosome biogenesis. We found that cells lacking the endoso-
mal sorting complexes required for transport (ESCRT) compo-
nent ALIX, a critical mediator of exosome biogenesis (Bissig
and Gruenberg, 2014; Carlton, 2010), displayed enhanced
EGFR activation, suggesting unexpected parallels betweenmechanisms of exosome biogenesis and regulation of EGFR
activity. We found that PD-L1 is secreted on exosomes in an
ALIX-dependent manner, and impaired exosomal release
conferred an enhanced immunosuppressive phenotype on tu-
mor cells that was dependent upon EGFR kinase activity. Our
data suggest that downregulation of ALIX provides amechanism
for enhancing both EGFR activity and PD-L1-mediated evasion
of anti-tumor immunity in BLBC, driving cell-autonomous and
non-cell-autonomous mechanisms of tumor survival.
RESULTS
EGFRActivityMonitoring In SituUsing a FRETBiosensor
Fluorescence resonance energy transfer (FRET)-based biosen-
sors enable in situ monitoring of signaling pathway activities in
cells (Komatsu et al., 2011). The Picchu-X FRET biosensor (Kur-
okawa et al., 2001) is based on the CrkII adaptor protein, a direct
target of EGFR phosphorylation (Hashimoto et al., 1998). Here,
we use a modified version of Picchu-X that has been optimized
for fluorescence lifetime imaging (FLIM) to monitor EGFR activity
in HCC1954 BLBC cells.
Background biosensor activity in HCC1954 cells was low, indi-
cating a minimal basal EGFR activity (Figure 1A). We observed a
stimulation-dependent and PD168393-sensitive enhancement
of Picchu-X phosphorylation (Figure 1A) and FRET/FLIM (Figures
1B and 1C), demonstrating the biosensor’s specificity as a
readout of EGFR activity. The relationship between mean donor
lifetime and mean fluorescence intensity among untreated and
EGF-treated populations was incorporated into the analysis toCell Reports 24, 630–641, July 17, 2018 631
Figure 2. Picchu-X Screen to Identify Hits
Affecting EGFR Activity
(A) The protein interaction sub-network of the 20
hits identified in a high-content siRNA screen and
their connection to seed set proteins. The sub-
network was extracted from a larger network of
533 proteins obtained from the Human Protein
Reference Database (HPRD) based on their direct
associations with seed-set proteins and 1 (or more)
other network member (central rectangle indicates
primary seed or EGFR; white ellipses indicate
additional seeds; shaded polygons indicate screen
hits).
(B) FLIM-intensity scatterplots and associated
regression analysis of six example experimental
groups (three non-hits and three hits). Each data
point shows mean fluorescence lifetime plotted
against mean fluorescence intensity for a single
cell. Pearson correlation coefficients describe the
association between lifetime and intensity for the
EGF-treated (solid circles) and non-treated (empty
circles) subgroups, and the difference in r values
was used to evaluate the effects of target protein
KD on EGFR activity (*p < 0.05).
(C and D) Lysates of the indicated EGF-stimulated
HCC1954 cell lines were examined by western
blotting. Bar chart in (C) summarizes densitometry
analysis of phospho-EGFR levels normalized to
tubulin (n = 3 independent experiments ± SEM
(*p < 0.05, two-tailed Student’s t test). Similarly,
immunoblots for phospho-CrkII are shown in (D).
See also Figures S1 and S2.account for lifetime variations arising from differences in
biosensor expression levels (Figure 1D). The analysis confirmed
that the association between EGF treatment and lifetime was
unaffected by the level of biosensor expression (Figure 1E).
This stringent method of analysis was applied to all lifetime
data acquired from the high-content small interfering RNA
(siRNA) screen.632 Cell Reports 24, 630–641, July 17, 2018Identification of Regulators of EGFR
Using a FLIM-Based High-Content
Screen
We determined the effects of the tar-
geted knockdown of 533 candidate pro-
teins on EGFR signaling in situ to identify
regulators of EGFR among a network
of candidate proteins extracted from
a bioinformatics-led analysis of protein-
interaction databases (Figure S1).
Twenty hits were identified that abro-
gated the biosensor response to ligand
(Figure 2A, gray nodes; Figure 2B, cf. dif-
ference in the slopes of linear regression
lines for EGF versus non-EGF treatment
cell populations within the example
‘‘non-hit’’ and ‘‘hit’’ siRNA experimental
groups; Table S1). Details of the 20 hits
identified in the screen are provided in
Table S1, and their known interactionswith members of the EGFR subnetwork are illustrated in Fig-
ure S1 (pink nodes).
ALIX Is a Negative Regulator of EGFR Activity
Of the 20 proteins identified in our screen, 14 were identified
as exosomal cargo proteins (Table S2), suggesting that changes
in exosomal sorting can influence EGFR activation. There is
increasing realization that cancer cells can exploit the
exosomal pathway as a mechanism for driving tumor survival
and dissemination (Bissig and Gruenberg, 2014; Ghossoub
et al., 2014). Consequently, we sought to identify proteins
providing an interface between oncogenic EGFR and
exosomal components in BLBC. The expression of 12 of these
14 exosomal-related proteins has been confirmed in normal and
cancerous human breast tissues (Table S3). Of these, the
adaptor protein ALIX was selected for further investigation,
given its association with the exosomal cargo and intraluminal
vesicle (ILV) biogenesis (Table S2).
Using HCC1954 cells stably expressing ALIX short hairpin RNA
(shRNA), we confirmed that stimulation-induced EGFR phos-
phorylation was both enhanced and prolonged in ALIX knock-
down (KD) cells, when compared with non-targeting controls
(NTCs; Figure 2C). Elevated levels of downstream signaling com-
ponents (endogenous CrkII phosphorylation) were also observed
in these cells following EGF stimulation (Figure 2D). Results were
confirmed in SKBR3 breast cancer cells (Figure S2), demon-
strating that this phenotype was not unique to HCC1954 cells.
ALIX Controls Exosomal Cargo Incorporation
ALIX is implicated in the multivesicular body (MVB) sorting
pathway of ubiquitinated membrane receptors. This pathway is
responsible for cargo incorporation into ILVs, linking ALIX directly
to cargo sorting and exosome biogenesis (Baietti et al., 2012).
Therefore, in addition to altering EGFR activity, ALIX KD may
also affect the quality and composition of exosomes, with down-
streamconsequences for tumor biology. Although procedures do
not yet exist for the absolute purification of exosomes, sequential
ultracentrifugation provides an established technique for the
enrichment of extracellular vesicle (EV) subpopulations highly en-
riched with exosomes. Nanoparticle tracking analysis (NTA) re-
vealed that ultracentrifugation-enriched particles from HCC1954
culture supernatants had ameanmodal diameter of 86 nm,which
lieswithin the rangeof 40–120nmassociatedwithexosomes (Fig-
ure 3A). Examination of these particles by transmission electron
microscopy (TEM) revealed cup-shaped morphologies charac-
teristic of exosomes, while immunogold labeling confirmed that
they were positive for the exosome marker CD63 (Figure 3B).
Western blotting confirmed the presence of the exosomal marker
proteins TSG101, CD9, and ALIX (Figure 3C). Immunoblotting
analysis revealed theenrichmentand lossof positiveandnegative
exosomal markers, respectively, in these ultracentrifugations. A
visual analysis of extracellular vesicle preparations from
HCC1954 cells stably expressing GFP-CD63 revealed a uniform
field of fluorescent particles (Figure 3C), and a mass-spectrom-
etry-based comparison of sequential ultracentrifugation and
ExoQuick methods demonstrated that the centrifugation method
was associated with a lower amount of extracellular protein
contamination (Figure S3). Together, these data show that ultra-
centrifugation provides an effective method for the enrichment
of exosomes from HCC1954 culture supernatants.
To test whether ALIX depletion alters the exosomal proteome
of HCC1954 cells, exosomes from the culture supernatants of
control and ALIX KD cells were examined by quantitative mass
spectrometry. Liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS) identified a total of 3,700 proteins in the exo-somes of parental HCC1954 cells. These included the core
exosomal marker proteins CD63, CD9, and CD81 and proteins
known to be associated with exosome biogenesis and endoso-
mal trafficking, such as ALIX, syntenin, syndecan, and Rab5
(Figure S3).
Analysis of the exosomal proteome of ALIX KD cells revealed
that 12 proteins were significantly downregulated and four were
significantly upregulated, when compared with controls (Fig-
ure 3D). As expected, ALIX and syntenin (a cytoplasmic adaptor
protein known to interact with ALIX as part of the exosome
biogenesis machinery; Baietti et al., 2012) levels were signifi-
cantly diminished in exosomes derived from ALIX KD cells.
PD-L1 Is Mis-secreted in the Absence of ALIX
We were intrigued to find that PD-L1, a protein of high clinical
relevance because of its role in mediating tumor-associated
immunosuppression, was significantly depleted from the exo-
somes of ALIX-suppressed cells. Basal PD-L1 expression in
HCC1954 cells is elevated following cell stimulation with EGF
or interferon (IFN)g, the archetypal signaling factor associated
with PD-L1 expression (Figures S4A and S4B). Exosomal
PD-L1 incorporation correlates with cellular expression levels
(Figure 4A), and we discovered that, while IFNg treatment
resulted in the robust induction and sustained expression of
PD-L1 in both NTC and ALIX KD cells (Figure S4C), PD-L1 incor-
poration into exosomes was significantly reduced in ALIX KD
cells (Figure 4B). Flow cytometry analysis of cell-surface PD-L1
expression in unstimulated and IFNg-stimulated cells revealed
that surface levels were elevated in ALIX KD cells (Figure 5A).
These data suggest that exosomal release of PD-L1 occurs at
the expense of surface PD-L1 levels and that ALIX controls the
balance of receptor distribution between these membranes.
Because basal levels of PD-L1 are almost undetectable in
SKBR3 cells, and are unchanged following EGF or IFNg treat-
ment (Figure S5A), we used mouse KPB6 tumor cells, which
show a robust PD-L1 response to IFNg (Figure S5B), as an
alternative model to confirm the PD-L1 surface expression
phenotype. Elevated surface PD-L1 levels were confirmed in
ALIX-depleted and IFNg-stimulated KPB6 cells (Figure S5C).
ALIX Regulates PD-L1 Sorting onto ILVs
To gain insight into the mechanism underlying the reduced
exosomal packaging and enhanced cell-surface expression of
PD-L1 in ALIX KD cells, we examined the subcellular localization
of PD-L1. Immunocytochemistry revealed that, in addition to its
cell-surface localization, PD-L1 also localized to both the limiting
membrane and ILVs of CD63-positive MVBs in IFNg-treated
HCC1954 cells (Figure 5B). This was in agreement with our
detection of PD-L1 in the exosomes of IFNg-treated cells,
because ILVs are the intracellular precursors of these extracel-
lular vesicles. In ALIX KD cells, a greater proportion of PD-L1
was found at the limiting membrane of MVBs, rather than within
the endosomal lumen (Figure 5B). Because MVBs are small sub-
cellular structures, the presence of discrete intraluminal cargo is
difficult to discern by epifluorescence microscopy. We used
Rab5 Q71L expression to promote endosomal enlargement,
facilitating the distinction between limiting membrane and
endosomal lumen, which confirmed the limiting membraneCell Reports 24, 630–641, July 17, 2018 633
Figure 3. ALIX Regulates Exosomal Cargo
Incorporation
(A) Summary of nanoparticle tracking analysis
(NTA) showing the size distribution of EVs isolated
from HCC1954 culture supernatants by ultracen-
trifugation. Each trace is representative of individ-
ual NTA performed on five samples. Bar graph
shows mean modal size of exosomal and MV
fractions from n = 5 traces ±SD (***p < 0.0001, two-
tailed Student’s t test).
(B) TEM of exosomes; arrows indicate CD63
immunolabeling. Scale bars, 100 nm (left image)
and 50 nm (right image).
(C) Western blot demonstrating the presence of
exosomal markers ALIX, TSG101, and CD9 in
HCC1954 cell lysates and exosomes (equal protein
loaded per lane) and showing the enrichment of
these three exosomal markers in the correspond-
ing exosome lanes. Dot-blots demonstrate the
relative levels of positive and negative EV markers
in the lysates of cells (5 mg per spot) and EVs (1 mg
per spot) harvested after the indicated centrifuga-
tion steps. Epifluorescence images of GFP-CD63-
labeled EVs harvested after the indicated centri-
fugation steps are shown.
(D) Heatmaps of changes in the exosomal
proteome following ALIX KD in HCC1954 cells.
Heatmaps are of protein expression across control
(NTC) and ALIX KD (ALIX) samples and are dis-
played as row Z scores (each row is standardized
by subtracting the mean value and dividing by the
SD). Rows are ordered by mean fold change
between NTC and ALIX sample groups (n = 3 in-
dependent experiments; proteins with mean fold
change < 2 were excluded). For each treatment
group (NTC or ALIX KD), the column number de-
notes an independent biological experiment, while
the letter denotes a technical repeat. Gene name
repeats indicate alternative splice variants.
See also Figure S3.accumulation and luminal exclusion of PD-L1 in ALIX KD cells
(Figure S6A). Interestingly, TEM analysis of MVBs from NTC
and ALIX KD cells revealed that budding profiles (luminal invag-
inations of the limiting membrane of MVBs that are the precur-
sors to ILVs) were more frequently observed in ALIX KD cells,
when compared with controls (Figure S6B).When taken together
with the immunofluorescence data, these findings suggest that
there may be a defect in intra-endosomal budding associated
with ALIX depletion. These data suggest that ALIX is required
for incorporation of PD-L1 from the limiting membrane into
ILVs, which would account for the diminished levels of exosomal
PD-L1 and enhanced surface PD-L1 in ALIX-depleted cells.
ALIX Regulates the Immunosuppressive Properties of
BLBC Cells by Regulating Surface PD-L1 Expression
The observation that loss of ALIX expression is associated with
reduced exosomal packaging of PD-L1 and elevated cell-634 Cell Reports 24, 630–641, July 17, 2018surface expression raises the intriguing
possibility that cells with reduced ALIX
expression exhibit enhanced immuno-suppressive properties. To test this hypothesis, NTC and
ALIX KD cells were either untreated or stimulated with IFNg
for 24 hr and co-cultured with activated primary human
peripheral blood CD3+ T lymphocytes to observe the effects
of co-culture on lymphocyte proliferation. Flow cytometry
analysis of T cells revealed an impairment in the proliferation
of T cells co-cultured with ALIX-depleted tumor cells
(Figure 5C). These findings demonstrate that ALIX depletion
confers enhanced immunosuppressive properties on cancer
cells.
Given that PD-L1 expression increases following EGFR or
IFNg receptor activation, and given that ALIX both regulates
EGFR activity and modulates the exosomal and cell-surface
distribution of PD-L1, we sought to determine whether EGFR
signaling integrated with the IFNg:PD-L1 signaling axis by
examining whether the expression and cellular distribution of
PD-L1 induced by IFNg treatment in NTC and ALIX KD cells
Figure 4. Ligand-Induced Expression and
Exosomal Packaging of PD-L1 in HCC1954
Breast Cancer Cells
(A and B) Dot-blots (1 mg per spot) and associated
densitometry analysis showing the EGF- and/or
IFNg-dependent induction of PD-L1 protein
expression and exosomal packaging in HCC1954
cells (mean fold change ± SEM; *p < 0.05, two-
tailed Student’s t test) (A). (B) IFNg-dependent in-
duction of PD-L1 protein expression and exosomal
packaging in NTC or ALIX KD equivalent cell lines.
See also Figure S4.was dependent upon EGFR. Treatment of ALIX KD cells with
the EGFR inhibitor PD168393 prior to IFNg stimulation both
diminished the surface accumulation of PD-L1 (Figure 5A)
and reduced the immunosuppressive effect of these cells in
subsequent co-culture assays (Figure 5C). These data indicate
that EGFR signaling contributes to the IFNg- and PD-L1-
dependent immunosuppressive response and suggest that
ALIX integrates the signaling of two important regulators of tu-
mor-mediated immunosuppression, modulating PD-L1 surface
expression and the EGFR signaling required for the associated
immunosuppressive phenotype.
ALIX and PD-L1 Expression Levels Are Inversely
Associated in Human Breast Cancer
Our in vitro data suggest that modulation of ALIX expression pro-
vides a mechanism for regulating surface PD-L1 expression.
Furthermore, we show that differences in ALIX expression trans-
late into differences in immunomodulatory potency. To examine
the relevance of this ALIX:PD-L1 signaling axis in human dis-
ease, we performed a tissue microarray analysis of PD-L1 pro-
tein expression on 189 tumor samples across different human
breast cancer subtypes and combined this with ALIX gene
expression analysis using mRNA isolated from matched tissue
samples. Our analysis revealed a statistically significant inverse
correlation between ALIX mRNA and PD-L1 protein expression
in tumor cells (Figures 6A and 6B).CALIX Suppresses Tumor Growth
and the Immunosuppressive
Microenvironment In Vivo
We next wanted to evaluate the impact of
ALIX loss on the anti-tumor immune
response in vivo. For this, we used the
well-characterized and established syn-
geneic BALB/c mouse model with the
67NR breast cancer cell line, which dem-
onstrates robust induction of PD-L1 in
response to IFNg (Figure 6C).
Ex vivo analysis of the relationship
between lymphocytic invasion and the
ALIX:PD-L1 expression ratio in parental
67NR tumors grown in the mammary fat
pad of BALB/c female mice revealed a
complex intratumoral relationship in which
distinct regions of low ALIX:PD-L1 andhigh ALIX:PD-L1 expression ratio were associated with different
CD3+T cell counts (Figure 6C). Low-ALIX:PD-L1 ratio pixels
were less infiltrated by CD3+ T cells than the high-ALIX:PD-L1
ratio pixels within the same tumor (Figures 6C and 6D).
To determine the effects of ALIX depletion on tumor growth
and immunosuppression, we generated 67NR cell lines stably
expressing control and ALIX shRNAs and used them to induce
orthotopic subcutaneous tumors in mice. These in vivo studies
showed that ALIX loss resulted in significantly enhanced tumor
volume at day 14 (time of animal culling), when compared with
control tumor-bearing mice (Figure 7A). Furthermore, an
increased frequency of CD4+ regulatory T cells (Figure 7B) and
a decreased frequency of Granzyme B-expressing, tumor-infil-
trating CD4+ and CD8+ T cells (Figure 7C) were observed at
day 14. Together, these results suggest that reduced ALIX
expression contributes to the establishment of an immunosup-
pressive tumor microenvironment, leading to more aggressive
tumor growth.
These observations suggest that ALIX is a regulator of both the
surface expression and immunomodulatory potency of PD-L1 in
breast cancer, in part, through its regulation of EGFR.
DISCUSSION
EGFR is abnormally and heterogeneously expressed in breast
cancers (Nuciforo et al., 2015), and identifying factors that canell Reports 24, 630–641, July 17, 2018 635
Figure 5. ALIX Regulates the Immunosup-
pressive Properties of HCC1954 Cells via a
Redistribution of PD-L1
(A) Flow cytometry data and statistical analysis of
surface PD-L1 expression in NTC and ALIX KD
HCC1954 cells. Bars represent mean fluorescence
intensities ± SEM (**p < 0.01, ANOVA).
(B) Top: HCC1954 cells were transfected with
indicated siRNAs, treated with IFNg, fixed, stained
using antibodies against endogenous CD63 and
PD-L1, and counterstained with DAPI. The per-
centage of cells displaying endosomal PD-L1 was
calculated (bottom left graph, mean ± SD), and the
percentages of CD63-positive PD-L1 decorated
structures were scored: control, 63 ± 4.2%;
ALIX #1, 64 ± 4.7%, n.s. (not significant); ALIX #2,
59 ± 2.7%, n.s. 100 cells per experiment, n = 4.
Intraendosomal PD-L1 localization (right graph),
was also scored; 3,977 endosomes from 10 fields
of view per experiment were scored over 4 inde-
pendent experiments (mean ± SD, **p < 0.01, two-
tailed Student’s t test). Lysates were examined by
western blotting. Arrowheads highlight luminal and
limiting membrane accumulation of PD-L1 in
MVBs of control and ALIX KD cells, respectively.
Scale bars, 10 mm.
(C) Cell-tracker dye intensity histograms of CD8+
T cell proliferation from labeled T cell-tumor cell
co-culture assays. Cell proliferation indices are
shown for each treatment group with their
associated SEM (*p < 0.05 versus control
group; n: 5 independent experiments for each
treatment group). Bar chart summarizes the flow
cytometry data of surface PD-1 expression in naive
and CD2-, CD3-, and CD28-stimulated CD4+
and CD8+ T cell subpopulations (***p < 0.001,
Student’s t test; data are from n = 5 independent
experiments).
See also Figures S5 and S6.delineate patient subsets for more effective therapies is of signif-
icant clinical interest (Carey et al., 2012; Masuda et al., 2012).
EGFR and immune checkpoint combination strategies are
currently being tested in clinical trials (Ahn et al., 2016), and while
PD-L1/PD1 pathway blockade is a promising therapeutic
approach in oncology, our understanding of PD-L1 regulation
remains incomplete. Future success of combination therapies
will depend on better understanding of growth factor:PD-L1
signal crosstalk.
We have shown that ALIX is a negative regulator of EGFR
activity, that its depletion significantly augments IFNg-induced
PD-L1 surface expression in human breast cancer cells, and
that this upregulation is EGFR activity dependent. We have,636 Cell Reports 24, 630–641, July 17, 2018therefore, extended the receptor tyrosine
kinase (RTK) and immune checkpoint
molecular interdependence phenome-
non, previously only observed in EGFR
mutated lung cancers (Akbay et al.,
2013), to BLBC, where PD-L1 expre-
ssion is frequently observed and where
elevated EGFR expression is associated
with poor survival.PD-L1 has been identified in exosomes isolated from urine or
plasma (Moon et al., 2011; Sabapatha et al., 2006) but has not
previously been detected in the exosomes from cancer cells.
Using exosomal proteome profiling, we found that HCC1954
cells package PD-L1 into exosomes and that ALIX depletion
impairs this exosomal incorporation. Correlating with impaired
ILV and exosomal incorporation of PD-L1, ALIX-depleted cells
exhibit enhanced surface levels of PD-L1, conferring an
enhanced immunosuppressive phenotype on these cells. The
change in partitioning of PD-L1 between the exosomal and
cell-surface compartments was associated with an altered
pattern of PD-L1 localization at the endosome; namely, a loss
of luminal PD-L1 and an accumulation of this protein at the
Figure 6. In Vivo Relationship between ALIX
and PD-L1 Expression and Its Association
with Immune Cell Infiltrate
(A) Boxplot of PD-L1 protein expression according
to ‘‘low’’ (n = 95) or ‘‘high’’ (n = 94) ALIX mRNA
expression, where ‘‘low’’ and ‘‘high’’ indicate less
than and greater than the median value, respec-
tively (***p < 0.001, Mann-Whitney U, two-tailed
test).
(B) Fluorescence images of PD-L1 immunostain-
ing of representative breast cancer tissue speci-
mens associated with low (left) and high (right)
ALIX mRNA expression (dotted line indicates
the perimeter of tissue specimen). Scale bars,
100 mm.
(C) Western blot showing IFNg-dependent induc-
tion of PD-L1 in 67NR cells. Spatial analysis of
ALIX, PD-L1, and CD3 expression in tissue sec-
tions processed for analysis by immunofluores-
cence. Comparison of CD3+ cell position with
heatmaps of high and low ALIX:PD-L1 expression
ratios in 67NR tumors. Representative composite
images of CD3 channel (green) with ALIX:PD-L1
ratio heatmaps (red and blue). Heatmaps were
generated by applying a 2D Gaussian image blur
to a thresholded ALIX:PD-L1 ratio image.
Ratio images were thresholded for pixel regions
(>1 pixel) where the ratio > 2.0 (high ratio)
or < 0.5 (low ratio) after ALIX intensity values were
normalized to achieve a baseline ratio of 1.0.
Pixels where the ALIX:PD-L1 ratio was <0.5 (low
ratio) are more excluded for CD3+ T cell infiltra-
tion. Scale bar, 100 mm.
(D) Quantification of data from (C). Left panel: in
67NR tumors, the presence of CD3 correlates
with a higher heatmap value (CD3+ mean =
0.0115, SEM = 0.0002; CD3 mean = 0.00884,
SEM = 0.00005, Kolmogorov-Smirnov test,
p < 0.001). Right panel: representative baseline
correlation by randomizing the position of CD3
value (CD3+ mean = 0.00914, SEM = 0.0002;
CD3 mean = 0.00903, SEM = 0.00006,
Kolmogorov-Smirnov test, p = 0.6). A total of 12
images were analyzed. Boxplots represent
30,000 20 3 20 pixel regions.limiting membrane. We suggest that defective ILV incorporation
of PD-L1 results in impaired exosomal packaging, and upon
MVB-PM (plasma membrane) fusion, this results in an elevation
of cell-surface PD-L1 that confers an enhanced immunosup-
pressive phenotype. It should be noted that, given its role in viral
budding, ALIX may also contribute to the formation of plasma
membrane microvesicles, which could contribute to the PD-L1
cell-surface phenotype. However, our immunocytochemistry
data indicate that defective trafficking (limiting membrane to
ILV) of PD-L1 within MVBs is likely to be a major contributor to
this phenotype.CAnalysis of tissue microarrays from
diverse human breast cancer subtypes re-
vealed PD-L1 upregulation in tissues with
low ALIX mRNA levels. Previous studies
observed that PD-L1 expression is hetero-geneousamongdifferentbreast cancersandhasaprognosticand
predictive value in breast cancers (Sabatier et al., 2015). Among
breast cancer subtypes, BLBC cells constitutively express the
highest levels of PD-L1 (Soliman et al., 2014). Furthermore,
PD-L1 overexpression is more prevalent in inflammatory breast
cancers (a rare and particularly aggressive form of disease) that
are ER (estrogen receptor) negative, basal, and ERBB2 enriched
(Bertucci et al., 2015). Our data confirm that PD-L1 expression is
higher in basal-like cancers and show that PD-L1 is upregulated
in tumor tissues with low ALIX mRNA levels, independently of
cancer subtype.ell Reports 24, 630–641, July 17, 2018 637
Figure 7. ALIX Deficiency in an In Vivo
Model of Breast Cancer Induces an Immu-
nosuppressive Tumor Microenvironment
(A) Breast tumors were induced by bilateral
subcutaneous injection with control (black circle)
or ALIX-KD (black triangle) 67NR cells and were
monitored for up to 14 days. Western blot
demonstrates stable KD of ALIX in 67NR cell
lines.
(B and C) Tumor immune cell infiltrate was
analyzed for the presence of regulatory T cells
(B; Treg, CD4+CD25+Foxp3+) and cytotoxic
T cells (C; Granzyme B expression). Plots shown
are derived from gates for live CD45+CD3+ cells.
The results in the three panels are representative
of 8 NTC and 16 short hairpin (sh)ALIX tumors
growing in 4 and 9 mice, respectively. Data for the
two stable ALIX shRNA 67NR cell lines were
pooled for the analysis.Ex vivo quantitative immunofluorescence analysis of 67NR
mouse tumor tissue sections revealed an intratumoral associa-
tion between areas of low ALIX:PD-L1 expression ratio and a
reduced CD3+ lymphocytic infiltration. While this association
was significant, it should be noted that it was not observed
uniformly, and it is likely that analysis was confounded by the
presence of non-tumor cell types expressing ALIX and PD-L1.
Spectral deconvolution of more cell-type-specific fluorescent
markers will be required to delineate further this phenomenon
of relative T cell exclusion from low-ALIX, high-PD-L1 tumor
cells.638 Cell Reports 24, 630–641, July 17, 2018The generation of stable ALIX-
suppressed 67NR cells enabled us to
address directly the pathophysiological
consequences of ALIX depletion on tumor
growth and immunosuppression. 67NR
cells can be used with immunocompetent
BALB/c mice as a syngeneic model of
breast cancer and provide an ideal tool
to study tumor–immune interplay in this
disease. Our in vivo studies revealed
that ALIX-KD tumors were both larger
than control tumors and associated
with an enhanced immunosuppressive
phenotype that included elevated
numbers of infiltrating T-regulatory cells
and decreased numbers of granzyme-B-
expressing, tumor-infiltrating CD4+ and
CD8+ T cells.
Taken together, our data strengthen
the link between the tumor microenviron-
ment and suppression of the immune
system in human breast cancers by
shedding light on the signaling interplay
between EGFR, ALIX, and PD-L1. These
data will open additional avenues for
therapeutic strategies and accelerate
biomarker discovery programs to opti-mize future combinations between EGFR and immune check-
point targeting.
EXPERIMENTAL PROCEDURES
Antibodies
Details of antibodies used in this study are provided in Table S4.
Cell Culture
Human HCC1954 and SKBR3 breast cancer cells were cultured in RPMI 1640
andDMEM, respectively. Mouse 67NR breast and KPB6 lung cancer cells were
cultured in DMEM and IMEM, respectively. Culture media was supplemented
with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin, and
100 mg/mL streptomycin. Cell lines stably expressing NTC and ALIX shRNAs
were generated by lentiviral transduction using the pGIPZ system (GE Health-
care UK, Buckinghamshire, UK). Stable cultures of virally traduced cells were
established by puromycin selection.
High-Content siRNA Screen
The custom-designed Silencer Select Human siRNA Library, comprising
siRNAs for 533 human gene targets (three siRNAsper target), was fromApplied
Biosystems. siRNA dilutions, transfection complex preparation, and cell seed-
ing were performed using a Janus automated workstation (PerkinElmer).
Each siRNA was evaluated in triplicate, and each experiment was performed
three times. Cells were seeded in the presence of transfection complexes
(0.5 pmol siRNA; RNAiMAX reagent, Invitrogen, Carlsbad, CA, USA) and, after
24 hr, were transfectedwith the Picchu-X biosensor using FuGENEHD reagent
(Promega, Fitchburg,WI, USA). After an additional 24 hr, cells were treatedwith
or without 100 ng/mL EGF for 30min before fixation and FLIM analysis. Control
siRNA cells were included alongside target siRNA cells to enable pairwise
comparisons. siRNAs against human PDCD6IP were purchased from Horizon
Discovery (Cambridge, UK). PDCD6IP siRNAs #1 and #2 refer to siGENOME
IDs D-004233-01-0002 and D-004233-06-0002, respectively. siGENOME
Non-Targeting siRNA ID D-001210-02-05 was used as the control. Lentiviral
shRNA vectors for the stable KD of human and mouse PDCD6IP were
purchased from GE Healthcare UK. For stable KD of human PDCD6IP, Clone
ID V2LHS_357889 was used. For stable KD of murine Pdcd6ip, Clone IDs
V2LMM_177842 and V3LMM_450035 were used.
FLIM Analysis
FLIM was used to measure FRET between the donor and acceptor fluoro-
phores of the biosensor in cells treated with or without EGF. Because high
biosensor expression increases the probability of intermolecular FRET be-
tween the donor and acceptor fluorophores of neighboring proteins through
molecular crowding, such effects were considered in the analysis of intramo-
lecular FRET (desired component). Intermolecular FRET was determined by
analyzing the lifetime of the donor fluorophore at increasing concentrations
of biosensor expression (determined by fluorescence intensity). Pearson cor-
relation was used to examine the correlation between lifetime and intensity.
Regression analyses were further used to quantify associations between
EGF treatment, intensity, and lifetime. Tests for an interaction incorporating
the product term of EGF treatment and intensity were performed to assess
whether effects of EGF on lifetime differed by intensity. A lack of significant
interaction indicated that the association between lifetime and EGF treatment
was not affected by intensity (Figure 1E). Analyses of covariance (ANCOVA)
were performed to further discern the effect of EGF treatment, with intensity
and EGF treatment as predictor variables and biosensor lifetime as the
dependent variable. Lifetime and intensity data were normally distributed. All
statistical analyses were performed with R v3.1.2 (R Project for Statistical
Computing, Vienna, Austria). Two-tailed p values < 0.05 were considered
statistically significant. In all cases, data are presented as mean ± SEM.
Construction of the Picchu-X Biosensor
The Picchu-X sensor for reporting EGFR kinase activity was a kind gift fromM.
Matsuda, Osaka University, Osaka, Japan (Kurokawa et al., 2001). The CrkII-
based sensing region was excised and inserted into the equivalent sensing
portion of the previously described Raichu-Rac 1011-X sensor (Vega et al.,
2011), resulting in the generation of the EGFP-CrkII-mRFP1 biosensor with a
C-terminal membrane-targeting CAAX motif.
Exosome Isolation
HCC1954 cells at approximately 80% confluency were washed with PBS and
then cultured for 24 hr in FBS-free media. Culture supernatants were then
collected, and exosomes were enriched by sequential centrifugation. Briefly,
supernatants were centrifuged at 300 3 g for 10 min to remove cell debris,
at 5,000 3 g for 20 min to remove large vesicles and membrane fragments,
at 12,200 3 g for 60 min to deplete MVs, and then at 100,000 3 g for
120 min to pellet exosomes. The pellet was washed in PBS and then centri-
fuged at 100,000 3 g for an additional 60 min before resuspension in PBS.All steps were performed at 4C. NTA was performed using a Nanosight
LM10-HS (Nanosight) as described previously (Dragovic et al., 2011), using
constant flow injection. The NTA analysis softwarewas used to obtain informa-
tion regarding the particle population size distribution including the derivation
of the population’s modal particle diameter. Samples for mass spectrometry
were prepared and analyzed as described previously (Turriziani et al., 2014).
Further details of the procedure are provided in the Supplemental Experi-
mental Procedures.
Immunoblotting Assays
Western blotting was performed according to standard protocols. Dot-blotting
was used to examine protein content of EVs due to its improved sensitivity
compared with western blotting and involved the immunodetection of proteins
spotted onto nitrocellulose membranes (1 mg total protein in 5 mL). All primary
antibodies used are listed in Table S4. Densitometry analysis of protein band
(western blots) and spot (dot-blotting) intensities was performed using ImageJ
software. Data reported in bar graphs were obtained from R3 independent
experiments.
TEM
TEM was performed on a Joel 1010 electron microscope (Joel, Warwickshire,
UK). Exosomes were layered onto Formvar carbon-coated copper grids. Grids
were washed with H2O, and then incubated with 2% uranyl acetate (negative
stain) for 30 s. For immunogold labeling, exosomes layered onto Formvar
carbon-coated nickel grids were fixed with 0.5% paraformaldehyde (PFA)
for 4 min and then blocked with serum at room temperature for 10 min.
Exosomes were stained overnight at 4Cwith primary antibody against human
CD63, washed three times in PBS for 10 min, and subsequently labeled with
secondary antibody (10 nm colloidal gold, BioCell) at room temperature for
90 min. The immunolabeled exosomes were washed with PBS for 5 min, fixed
in 1% glutaraldehyde, and then washed twice with PBS and once with H2O.
Exosomes were negatively stained as described earlier before imaging.
Confocal Imaging
HCC1954 cells were transfectedwith ALIX siRNA (40 nM) usingRNAiMAX. After
48 hr, cells were treated with IFNg (20 ng/mL) for 24 hr. Cells were fixed with
PFA and stained for CD63 and PD-L1. Nuclei were counterstained with DAPI.
Cells were imaged on a spinning disk confocal microscope (Nikon Eclipse,
teamed with the CSU-X1 Andor Spinning Disk with Neo sCMOS camera),
acquiring sub-saturated images as z stacks with 0.3-mm Z-spacing. At least
10 fields of view per treatment were captured, and luminal versus limitingmem-
brane staining of endosomal PD-L1was scoredbymanually scrolling throughZ.
Tumor Cell-T Cell Co-culture Assays
Peripheral blood mononuclear cells (PBMCs) from healthy donor blood were
collected by sucrose gradient centrifugation using Ficoll (GE Healthcare).
CD3+/CD25 cells were subsequently isolated using magnetic beads (Miltenyi
Biotec), labeled with eFluor 450 cell-tracker dye, and then activated with CD3,
CD2, and CD28 beads at the time of co-culture with tumor cells. At 96 hr post-
co-culture, cells were recovered and stained with CD3, CD4, CD8, and PD-1
antibodies and then subjected to flow cytometry. Data were analyzed
using FlowJo software (FlowJo, Ashland, OR, USA). The significance of statis-
tical differences between treatment groups was determined using ANOVA
(p < 0.05 was reported as significant).
In Vivo Breast Cancer Model
Experiments were performed in accordance with the UK Home Office Animals
Scientific Procedures Act, 1986, and the United Kingdom Co-ordinating
Committee on Cancer Research (UKCCCR) guidelines. Tumors were estab-
lished by subcutaneous injection of 13 106 cells of the syngeneicmouse breast
cancer cell line 67NR (Aslakson andMiller, 1992) into themammary fat pad of 6-
to 8-week-old BALB/c female mice (Charles River UK). Tumor growth was
monitored with calipers and recorded every other day for 2 weeks; then, mice
were culled and primary tumors were dissected. Tumors were minced and
incubated for 1 hr at 37C in digestion media (RPMI containing 1 mg/mL type
2 collagenase and 0.1 mg/mL bovine pancreas DNase I) and passed through
a 40-mm cell strainer to form single-cell suspensions for flow cytometry.Cell Reports 24, 630–641, July 17, 2018 639
Flow Cytometry
Cell suspensions were stained with Zombie Aqua dye, followed by membrane
staining with anti-CD45-AF700, CD3-PECy7, CD4-BV785, CD8-PerCpCy5.5,
and CD25-PE; fixation and permeabilization; and intracellular staining with
anti-Foxp3-eFluor 450 or Granzyme B-APC. Stained cell suspensions were
analyzed by flow cytometry. Data were acquired in a Fortessa II flow cytometer
(BD Biosciences) and analyzed with FlowJo software (FlowJo).
Patient Samples and Immunohistochemistry
Tissues and data were collected by the KHP Cancer Biobank with approval
from the East of England – Cambridge East Research Ethics Committee, refer-
ence number 12/EE/0493. Tissue microarrays (TMAs) of 218 primary breast
cancers from the METABRIC study (Curtis et al., 2012) were used in this anal-
ysis. After antigen retrieval using the Ventana BenchMark system (Ventana
Medical Systems), tissues were stained with anti-PD-L1 antibody. A total of
189 TMA cores were imaged using an ‘‘open’’ high-content microscope
(Barber et al., 2013), and image data were subsequently processed to deter-
mine protein expression. To find the percentage of PD-L1-positive cancer
cells, we adopted a previously reported algorithm (Camp et al., 2002; Moeder
et al., 2009; Wimberly et al., 2015).
For the evaluation of ALIX mRNA expression, Illumina HT-12 microarray
expression data were obtained from all METABRIC samples and filtered to re-
move arrays with outlying low intensity (mean log2 expression < 5.6). Array
data were then quantile-normalized, filtered for probe detection (required
p < 0.01 for >1% of King’s METABRIC samples), and COMBAT-corrected
for beadchips. Normalization was performed using the ‘‘beadarray’’ package
for R/Bioconductor (Dunning et al., 2007). ALIX (PDCD6IP) mRNA expression
was inspected using Probe identifier ILMN_1693259. Gene expression data
from the METABRIC study have been reported previously (Curtis et al.,
2012). The correlation between PD-L1 positivity and ALIX mRNA tissue
expression was tested using GraphPad statistical analysis software.
Tissue samples and data from patients were obtained from The King’s
Health Partners (KHP) Cancer Biobank at Guy’s Hospital (London, UK; REC
no.: 07/40874/131).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and four tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2018.06.066.
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